great changes our has with considerably stronger to XXXX. management begin The like a even I'd team. and to and Tom. stronger the for close Thanks, become we're positioned to team XXXX
in adoption technologies will strategy access General and experienced leader Pacific Frank the record both He indirect of building three-decade of and First markets has a long creating commercial a VP Vandeputte, our Asia operations. track and needed Manager and our driving has and European and appointed make direct centers been we're of excellence. highly innovative businesses. new launching Frank to ensure global changes
well corporate Sighted as Next Gregoire our Clinical priorities focusing will RP to Orion of Affairs. will and role European market Orion in assumed efforts of patient RP will now Sight's of of the Cosendai, formerly the as Second on with Better of initiation Better I Operations clinical He initiation goals. VP subjects. trial lead be trials Sighted our has expanding trial to turn His the feasibility our XXXX Germany. the like first VP
Bob are making goals. As all our of against progress great we stated mentioned
in a traction model centers First, and on an we excellence are of are number centers cases perform North America our of seeing getting with increasing regular Argus schedule.
and patients. the retina Second preparing encouraging Sighted to with German we RP our programs innovative are is of for testing begin results proceeding trial stimulation Better
this human and program end to continues against subjects prepared year. to clinical and company Orion execute related to we're the goals the first the our R&D Finally, of all regulatory implant by
on remain and ambitious Our to with track achieve and we expect execution goals but them. are focus
centers XXXX two plan QX we into had in excellence. zero is new now compared center North with quarter Let's in of to rate QX. four the higher QX this will our and and ongoing centers expectations our rate detail on agreement centers add carefully perform we at of coverage. excellence regional selected an York progress mutual or six expanded centers two centers In saw to clear of with brings implanting more implanting another in we strategy reimbursement America XXXX. in number new little of new one in at QX exclusive At with the a Each which an dive total to centers end added expectation of as centers of the some per accomplishments. refined New that
four centers QX the in already rate new with in fact, three well XXXX above implants In an planning per targeted three the added in scheduled new contributed surgeries one end. additional and year quarter are before have of
strong with forward began look before quarter fourth momentum we delivering fourth in Finally, the to our to and America quarter. North a turning strong database,
us, critical Our serves of volume our year maintain to four excellence earlier to is the is to for as of that independent and become goal an of which person planning center teams. the and patient least a our medical on us telephone for centers screen greater quarter of rehab the independently passed patients asset funnel significant important our few continues per This patients the candidates site, patient who database we most and in post-surgery have valuable excellence. last predictability an candidates grow, component professional. patient by Last database contains has qualified calls our it strategy highly a discussed another we adopted of our allowing at a efficient XX
seeing QX XX months surgery We that patients to from grew growth are this number report have As qualified. of list database. list ultimately our aggressively database now the X/Xrds investing come of II that we of move we treated from the for to from being Argus last in the independently year X December and since being been can estimate this the candidates Recall with screened. within we qualify X dominant end patient and forward will
on a an U.S. Sighted RP base the Better I eligible not the point or also in Argus expanded label for move eligible our patients patients. I the for are Orion like Before includes that be of that that would out portion may also
options some future. the of every North we quarter for candidates we for holiday typically in other qualify expanded our difficult mixed fact, in Outside had treatment quarter were results many multiples Europe of is Argus a there today in the implants. able as in countries. schedule our summer for challenging given a In of QX consideration implants our terms patient America, are of for elective now are to patient database in
America we those we're quarter the better momentum as I'm be final North confident like the a in markets. from our year Frank of well. into more and With indirect growth expect much on on curve results direct seeing soon markets will Fortunately, heading predictable significant and board,
and now noted Turning a morning outpatient in press surgical rate Argus implantation this issued CMS reimbursement, II $XXX,XXX Medicare XXXX payment final our release for as of associated to for the procedure.
this pleased this drive outcome the opportunity centers and in additional We are XXXX. excellence provides adoption with to with of
the of or Our approximately the Medicare now coverage in XX% includes U.S. XXX U.S. population. million
we're XXXX, our made determining coverage growing half technology team with recent in will affected demonstrates in the policy. it evaluation three acceptance the concerns. them reimbursement the of final start like have their coverage addressed negative the we've recently In progress and decision program based MACs with received soon. our our of through medical we've of making I'd of we that will Canada We for continue the reversal with met remaining dialogue Health be England technology and Argus commissioning be to decision expect renowned the Argus this directors this from was recommendations only NHS as note on positive serve worldwide all is we will II, Technology tentative organizations assessments. this previous procedures. their of the confirmed to Advisory interactions reimburse by for first OHTAC's a to does Not bellwether as If study OHTAC a OHTAC Ontario II Committee, decision others for its good until with RCTE the
are also reimbursement our making national and reimbursement in relevant regions. are progress A submitted in in have information recently is and clinical authority and to for expanding the Belgium. good Turkey application under in additional Italy review we in economic decisions final reimbursement We several waiting still
RP turn population technology. a submitted made treat our larger we've clinical This patient significant Sighted significant approximately to progress, approved Argus with authorities is XX the current a population patients trial German trial RP the to treat. where clinical [ph] we is targeting our protocol because we Better Now that it's than of let's patients Indian for
indication XXXX. in plan with to similar FDA a expanded also pursue We
Argus improve ramping by stimulation system. during begun outlined and promising The testing. in next into changes we of provided up for advanced If actual our current continue only are patient most programs, usefulness and calls to the generation and these have develop the algorithms we an vision system have retinal the test programs been patients advanced our past which As could quality testing incorporated stimulation Argus testing has clinical QX. require developing Simultaneously retinal we artificial software been Argus, successful in program a camera new testing more Last year eye next submissions thereafter. new in powerful and to it be addressed times with specifically We're moving progress address retinal which is a the patient new with because wear, fronts, population least with many the unit. all the technology regulatory prosthesis. human than is track to these processing larger certainly a externals externals on forward Orion a blindness shortly has on can that early important begin potential but with not video
approval Bob, August by conditional lifted their by has FDA on As outlined the conditions in company prior XXth. the announced
before in We end year. implant in Medical UCLA approvals the We are Houston. U.S. at finalizing our and Center contracts first Baylor obtaining final the the in anticipate of IRB
pursuing also program. FDA's in are We participation devices the breakthrough
for objectives if cost move offers closing that As to the our of the most significantly adoption In a and process an gained in the innovative centers and with address executing. on commercialization clinical name America drivers we model centers. to program important by In meet streamlined number from of the for could traction focusing needs, has medical be unmet this North to continue excellence regulatory the time increasing development demonstrated year applies reduced. technologies accepted by
U.S. in are patients our and resulted covered U.S. population have new by markets growing include number we million. Taiwan, in Outside Korea our have database America the Russia. promising of XX We and efforts ever-increasing increase reimbursement large North the patient including qualified of of South a an entered to almost
commercialization. close treating of we treatable ground-breaking And this away, Our no agencies soon patients. program with the the clinical to are as concerning we patient first of population significantly discussions are RP something is the Better will scheduled our with Orion our ultimate several lastly technology forward expanding with years and to longer begin programs promise Vision moving RP regulatory path
Finally, will I proceed With the co-workers at that of and hard Second Sight dedication our their I call blind. want questions. please to to with my to thank for mission the instructions. for Operator, work sight giving open dedicated
